Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

Please provide your email address to receive an email when new articles are posted on . Mean change from baseline in UHDRS TMC score was more significant in patients treated with valbenazine compared ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

Credit: FDA. The new sprinkle formulation is intended to be opened for sprinkling on soft foods prior to administration. The Food and Drug Administration (FDA) has accepted for review the New Drug ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...

Chorea and hemiballismus are both forms of involuntary movement disorders. Hemiballismus can cause sudden, violent, and flinging motions. Chorea can cause irregular, spontaneous, and nonrepetitive ...